Treatment of Helicobacter pylori infection: Current and future insights

Maliheh Safavi, Reyhane Sabourian, Alireza Foroumadi

Abstract

Helicobacter pylori (H. pylori) is an important major cause of peptic ulcer disease and gastric malignancies such as mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma worldwide. H. pylori treatment still remains a challenge, since many determinants for successful therapy are involved such as individual primary or secondary antibiotics resistance, mucosal drug concentration, patient compliance, side-effect profile and cost. While no new drug has been developed, current therapy still relies on different mixture of known antibiotics and anti-secretory agents. A standard triple therapy consisting of two antibiotics and a proton-pump inhibitor proposed as the first-line regimen. Bismuth-containing quadruple treatment, sequential treatment or a non-bismuth quadruple treatment (concomitant) are also an alternative therapy. Levofloxacin containing triple treatment are recommended as rescue treatment for infection of H. pylori after defeat of first-line therapy. The rapid acquisition of antibiotic resistance reduces the effectiveness of any regimens involving these remedies. Therefore, adding probiotic to the medications, developing anti-H. pylori photodynamic or phytomedicine therapy, and achieving a successful H. pylori vaccine may have the promising to present synergistic or additive consequence against H. pylori, because each of them exert different effects.

Key words: Helicobacter pylori; Therapeutic regimens; Probiotics; Photodynamic; Phytomedicine

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This article aimed to provides a review of
current therapeutic options and the efficacy of some recent regimens. Also, essential need to new therapeutic agents such as probiotics, phytotherapy, photodynamic therapy and protective vaccine are described.

Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases 2016; 4(1): 5-19 Available from: URL: http://www.wjgnet.com/2307-8960/full/v4/i1/5.htm DOI: http://dx.doi.org/10.12998/wjcc.v4.i1.5

INTRODUCTION

Helicobacter pylori (H. pylori) is spiral in shape with a flagellum, gram-negative, micro aerophilic bacterium which colonizes in the human gastric mucosa, and the infection may last for decades. It is thought H. pylori infection to be the most common bacterial infection, and influence approximately 50%-75% of the population all over the world[4]. H. pylori is the main reason for the upper gastrointestinal diseases, including peptic ulcer disease (gastric and duodenal), chronic gastritis, gastric cancer and gastric mucosal-associated lymphoid tissue lymphoma[2].

Along with upper gastrointestinal tract problems, H. pylori caused chronic and low-grade inflammation in the gastric mucosa that could lead to some metabolic disorders. H. pylori infection may be correlated with insulin resistance, increased total and low density lipoprotein cholesterol and decrease of high density lipoprotein in infected peoples[5]. Also, H. pylori has a critical role in the other extragastric diseases such as chronic urticaria[6].

Although a variety of treatment regimens have been proposed for the eradication of H. pylori in order to achieve more effective eradication resistance[5]. In recent years, regimens that utilize proton-pump inhibitors (PPIs) in combination with several antibiotics such as amoxicillin plus clarithromycin or metronidazole have been considered as the first-line treatment for H. pylori infection[6]. PPI-based triple therapy has been described to be losing its efficacy for H. pylori, with eradication cure rates as low as 50% to 70%, due to high rates of antibiotic resistance, high rates of antibiotic-associated side effects and low compliance[5]. Decreased eradication rate has led to the development and use of new first-line treatment[4,7]. In some countries, new first-line treatments are not accepted because of a lack of national validation studies and a lack of studies of clarithromycin resistance[7].

The Maastricht IV/Florence Consensus Report recommended the bismuth-containing quadruple therapy as an alternative for first-line empirical treatment in areas with the clarithromycin resistance over 15%-20%. If this regimen is not available sequential therapy or a non-bismuth quadruple therapy (the so-called “concomitant” treatment) is recommended[8]. After failure of a PPI-clarithromycin-containing treatment for H. pylori infection, either a bismuth-containing quadruple therapy or levofloxacin-based triple therapy is recommended as second-line treatment or rescue therapy[8,9].

In patients with penicillin allergy, for a first-line treatment, the bismuth containing quadruple therapy appear to be a better choice than a PPI-clarithromycin-metronidazole combination regimen[10]. As a rescue regimen, a levofloxacin containing regimen together with a clarithromycin and PPI represents a second-line treatment in the presence of penicillin allergy[8,10].

The Maastricht IV/Florence Consensus Report recommended the use of antimicrobial susceptibility testing (culture-guided therapy), after the failure of second-line treatment[6]. However, culture-guided third-line therapy has been advised, but if antimicrobial sensitivity data are not available, an empirical triple or quadruple therapy can be recommended as third-line regimen[11].

As such, during the last 30 years that the H. pylori was identified, there have been numerous therapeutic regimens suggested but a unique most effective and least harmful therapeutic regimen to cure H. pylori infection in all reported colonized individuals is still lacking[12].

THERAPEUTIC OPTIONS

Antimicrobial agents

Despite the number of studies, the optimal treatment for H. pylori infection has not been found and routine clinical treatments are usually triple or quadruple antibiotic therapies[13].

Prevalence of antibiotic resistance to various antimicrobials varies in different geographical regions, and is associated with the consumption of antibiotics in those areas[14]. The most commonly used antibiotics are imidazole (metronidazole or tinidazol), macrolide (clarithromycin or azithromycin), tetracycline, amoxicillin, rifabutin and furazolidon[9,11]. Bismuth, a heavy metal with anti-H. pylori activity is used in bismuth-based quadruple therapy and seems almost totally maintains high eradication rates, independent of antibiotic resistance[16,17].

A survey of antibiotic resistance to the four commonly used antibiotics against H. pylori in Vietnam from July 2012 to January 2014 showed that 42.4% were resistant to clarithromycin, 41.3% to levofloxacin, 76.1% to metronidazole, and 1.1% to amoxicillin[18].

A cross-sectional study with collection of gastric biopsies in the United States from 2009 through 2013 showed the prevalence of H. pylori resistance to levofloxacin was 31.3%, to metronidazole it was 20.3%, to clarithromycin it was 16.4%, and to tetracycline it was 0.8%. No isolate exhibited amoxicillin resistance, but clarithromycin resistance increased from 9.1% in 2009-2010 to 24.2% in 2011-2013[19].

Results on antibiotic resistance in two time, the first time period (2000) and the second period (2010)
in Greece revealed during the first time period 30% and 0% of patients were infected with clarithromycin or quinolone-resistant strains but, in the second time period (2010), the resistance rate to clarithromycin or quinolone increased to 42% and 5.3%, respectively.\textsuperscript{[20]}

A systematic review of literatures on H. pylori antibiotic resistance carried out in Iran within the time span of 1997 to 2013. The incidence of H. pylori resistance to various antibiotics, including metronidazole, clarithromycin, furazolidone, amoxicillin, tetracycline, ciprofloxacin, levofloxacin was 61.6%, 22.4%, 21.6%, 16.0%, 12.2%, 21.0% and 5.3%, respectively\textsuperscript{[21]}. Compared the results from different countries showed prevalence of H. pylori resistance to various antibiotics is not the same and may be changed in time even in the same population.

Overwhelming evidence indicates that in order to determine an appropriate antibiotic in drug regimen against H. pylori infections, information on antibiotic susceptibility of the bacterium within different geographical areas of world is required.

**Antisecretory agents-PPI**

H. pylori treatment involves combination of antimicrobial and anti-secretory agents for 7 to 14 d. PPIs inhibit the parietal cell H⁺/K⁺ adenosine triphosphatase (ATPase), the enzyme of canalicular membrane of gastric parietal cells which is responsible for the last step in gastric acid secretion\textsuperscript{[22,23]}. Inhibition of this enzyme is more efficient than H2-receptor antagonists in suppressing gastric acid secretion\textsuperscript{[24]}.

At low pH, gastric PPIs as acid-activated pro drug transform to a spiro intermediate of dihydrobenzimidazole, then undergoes aromatization to a sulfenic acid followed by dehydrogenation to form a tetracyclic sulfonamide\textsuperscript{[25]}. PPIs bind to different cysteines in the \( \alpha \) subunit of the H⁺/K⁺ ATPase and inhibits the enzyme\textsuperscript{[26,27]}.

PPI with anti-secretory effect declines the acid production from stomach, which allows the tissues damaged by the infection to heal. PPI can also make acid-labile antibiotics more stable by elevation of the gastric pH, and also may alter luminal concentrations of antibiotics by transporting of antibiotics from plasma to gastric juices and elevating the success rate of eradication\textsuperscript{[28,29]}

The differences in pharmacokinetics for example elimination half-life, bioavailability and metabolism of currently available PPIs may translate in differences in clinical outcomes\textsuperscript{[30]}. All PPIs have good oral bioavailability and all PPIs except tenatoprazole undergo hepatic metabolism via the CYP isozymes CYP2C19 and CYP3A4, therefore with the elimination half-lives ranging from 1 to 1.5 h have the short elimination rate\textsuperscript{[31,32]}. Genetic polymorphism in CYP2C19 plays an important role in the metabolism of individual PPIs to different amounts, thereby affecting therapeutic effectiveness\textsuperscript{[32]}.

Several studies have produced conflicting data on eradication rates of H. pylori among CYP2C19 genotypes taking PPI based regimens\textsuperscript{[33]}. Some examples of the CYP2C19 pathway’s relative impact on the PPI metabolism have been demonstrated. The lansoprazole-based or omeprazole-based triple therapies were affected by CYP2C19 genotype status, whereas esomeprazole-based or rabeprazole-based triple therapies were not\textsuperscript{[30,33,34]}. The dosage and duration of treatment of PPIs for adults correspond to those that are able to suppress gastric acid secretion. Long-term omeprazole therapy in H. pylori positive patients induced changes in mucosal inflammation and glandular atrophy\textsuperscript{[35]}. Hypergastrinemia induced by PPI administration and corpus atrophic gastritis in patients with H. pylori infection might promote the development of gastric cancer\textsuperscript{[36]}.

**THERAPEUTIC REGIMENS**

**Dual therapy**

Dual treatments including a PPI with either clarithromycin or amoxicillin or metronidazole were popular during the previous decades. Dual therapy is now obsolete due to lack of efficacy of clarithromycin and metronidazole\textsuperscript{[37]}. On the contrary, worldwide primary and secondary resistance to amoxicillin of H. pylori is generally low and rare respectively, although it is a usual medication in standard triple therapy and therefore it is suitable for use in the dual therapy of H. pylori infection\textsuperscript{[9]}.

Amoxicillin is effective at high (> 5.5) pH environments. According to some controversial data, PPI in standard doses wouldn't be able in rapid metabolizers to achieved enough pH inhibition for effective antibiotic activity in mucus of gastric, determining lower eradication rates after therapy with regimens containing standard dose of PPI\textsuperscript{[38,39]}

Several studies assumed that there is direct and indirect demonstration which stated high-dose PPI, above the common standards, could ameliorate H. pylori treatment cure rates. The general idea in the back of high-dose PPI plus amoxicillin treatment is to overcoming resistance by altering the environment in which dormant H. pylori settled, thus inciting the bacteria to get in the replicative state and become sensitive to the antibiotics\textsuperscript{[40,41]}. In spite of the advantage of the low resistance rate to amoxicillin and theoretical advantages of high-dose PPI, it has been shown that the efficacy of high dose dual treatment is vary in different reports\textsuperscript{[30]}.

A number of recently different regimens for the H. pylori treatments are described in Table 1.

An open-label, prospective, single-center pilot study evaluated the effectiveness of amoxicillin plus high-dose PPI dual therapy for H. pylori eradication. The intention-to-treat (ITT) cure was achieved in 72.2% and in per protocol (PP) 74.2%, respectively\textsuperscript{[42]}. In an open-labelled and single-center prospective study, the overall success at eradication of H. pylori by two planned consecutive rescue therapies was tested.
The combination of nifuratel, bismuth subcitrate, and amoxicillin was a highly successful regimen in achieving eradication rate (> 90%) in Helicobacter pylori treatment failures.

In the ITT analysis, the result was positive in that dual therapy with the doses tested here was at least as successful as empiric triple therapy with a PPI, amoxicillin, and clarithromycin. Dual therapy is more effective, cost-effective and is less risky in terms of side effects compared to standard triple therapy in patients with dyspepsia but, however, compliance was 100% and reported side effects were mild and none interrupted therapy but dexlansoprazole, despite being administered at high dose, failed to achieve an intragastric milieu in treatment-naive patients.

Comparing effectiveness of standard 14-d regimen of triple therapy produce unacceptably therapeutic efficacy in China. Only levofloxacin-containing sequential therapy achieved borderline acceptable result.

Table 1 Numbers of different regimens for Helicobacter pylori infection treatments

| Regimens                                      | Patients (n) | Eradication rate                                      | Conclusion                                      | Ref. |
|-----------------------------------------------|--------------|-------------------------------------------------------|-----------------------------------------------|------|
| High dose dual therapies                      |              |                                                       |                                               |      |
| Amoxicillin 750 mg and esomeprazole 40 mg every 8 h for 14 d | 36           | The ITT cure was achieved in 72.2% (95% CI: 56%-84%) and PP cure achieved in 74.2% (95% CI: 56%-87%) | However, the regimen was not sufficient to eradicate 90% H. pylori but, the result was positive in that dual therapy with the doses tested here was at least as successful as empiric triple therapy with a PPI, amoxicillin, and clarithromycin. | [42] |
| Amoxicillin 1 g t.d.s. and rabeprazole 20 mg t.d.s. for 2 wk | 149         | Eradication success PP and ITT was 75.4% (95% CI: 68.3%-82.4%) and 71.8% (95% CI: 64.6%-79.0%), respectively. | Eradication success of 75% on PP analysis as a first rescue therapy including 2-wk high dose PPI-amoxicillin dual therapy was achieved. Following these patients by a second rescue therapy with PPI triple therapy were highly successful in achieving eradication rate (> 90%) in H. pylori treatment failures. | [43] |
| Amoxicillin 1 g b.i.d. and omeprazole 20 mg q.i.d. for 14 d | 74           | Eradication rate of 81.1% in the dual therapy group vs 63.8% in the triple therapy group was achieved | Dual therapy is more effective, cost-effective and is less risky in terms of side effects compared to standard triple therapy in patients with dyspepsia. However compliance was 100% and reported side effects were mild and none interrupted therapy but dexlansoprazole, despite being administered at high dose, failed to achieve an intragastric milieu in treatment-naive patients. | [44] |
| Amoxicillin 1 g and dexlansoprazole 120 mg each twice a day at approximately 12-h intervals for 14 d | 13           | PP and ITT treatment success were both 53.8% (95% CI: 25%-80%) |                                               | [41] |
| Amoxicillin 750 mg and rabeprazole 20 mg, 4 times/d for 14 d | 159          | In the ITT analysis, H. pylori was eradicated in 93.5% of treatment-naive patients (95% CI: 91.9%-98.8%) and in 89.3% of treatment-experienced patients (95% CI: 80.9%-97.6%) | High-dose dual therapy is superior to standard regimens as empirical first-line or rescue therapy for H. pylori infection with similar safety profiles and tolerability. | [45] |
| Triple therapies                               |              |                                                       |                                               |      |
| Amoxicillin 1 g and metronidazole 500 mg both three times a day plus esomeprazole 40 mg twice a day | 136          | Eradication rates were 82.4% (95% CI: 74.7%-88.1%) by ITT analysis and 88.2% (95% CI: 81.2%-92.8%) by PP analysis. | Cure rates of the combination of esomeprazole, amoxicillin and metronidazole are high and the treatment was well tolerated. | [47] |
| Amoxicillin 1 g twice daily, levofloxacin, 500 mg, once daily and esomeprazole 20 mg twice daily for 7 d | 345          | ITT analysis eradication rates were 78.1% (95% CI: 69.4%-85.3%), 78.3% (95% CI: 69.6%-85.4%), and 82.8% (95% CI: 74.6%-89.1%) for triple therapy, standard sequential therapy and levofloxacin-containing sequential therapy respectively and PP analysis eradication rates were 80.9% (95% CI: 72.3%-87.8%), 82.6% (95% CI: 74.1%-89.2%), and 86.5% (95% CI: 78.7%-92.2%), respectively, for the three therapies | Standard sequential therapy and 7-d levofloxacin triple therapy produced acceptably therapeutic efficacy in China. Only levofloxacin-containing sequential therapy achieved borderline acceptable result. | [48] |
| Amoxicillin 50 mg/kg per day, q.d.s., nifuratel 30 mg/kg per day, q.d.s. and bismuth subcitrate 8 mg/kg per day, q.d.s. for 10 d | 73           | PP and ITT treatment success were both 86% (95% CI: 76.6%-93.2%) | The combination of nifuratel, bismuth subcitrate, and amoxicillin was a tolerable and effective regimen for H. pylori eradication. | [49] |
| Amoxicillin 1 g, clarithromycin 500 mg and rabeprazole 20 mg, all twice daily for 10 d in comparison with half dose | 115          | Eradication rates were 77.6% (95% CI: 66.9%-88.3%) in the standard dose vs half dose 77.2% (95% CI: 66.3%-88.1%) on ITT analysis. PP eradication rates were 78.9% (95% CI: 68.4%-85.9%) and 81.5% (95% CI: 71.1%-91.8%) respectively. | A half-dose 10-d regimen is equally effective but cheaper and better tolerated than its standard-dose regimen. | [50] |
| Amoxicillin 1 g, clarithromycin 500 mg plus either omeprazole 20 mg or esomeprazole 40 mg twice daily for 1 wk | 200          | For patients classified as homogeneous extensive metabolizers, the PP H. pylori eradication rate was significantly higher in the esomeprazole group than in the omeprazole group (95% CI: 76%, P < 0.05). | Only for extensive metabolizers esomeprazole 40 mg twice daily for triple therapy improve the H. pylori eradication compared to omeprazole-based therapy. | [51] |
| Amoxicillin 1 g, clarithromycin 500 mg and lansoprazole 30 mg, all taken twice a day for 14 d | 1463         | Comparing effectiveness of standard 14-d regimen of triple therapy with that of the four-drug regimens given concomitantly or sequentially therapy showed the eradication rate with standard therapy was 82.2%, and concomitant therapy (73.6%) and finally by sequential therapy (76.5%) | Neither four-drug regimen was significantly better than standard triple therapy in any of the seven sites of Latin America. | [52] |
Quadruple therapies

| Quadruple therapies | The eradication rates according to ITT and PP analysis were both 95.8% (95% CI: 87.8%-103.8%) | The 10-d quadruple therapy achieves a very high eradication rate for *H. pylori* infection after failure of sequential therapy |
|---------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Tetracycline 500 mg q.d.s., levofloxacin 500 mg o.d., omeprazole 40 mg b.d. and tripotassium dicitratobismuthate 120 mg q.d.s. | PP and ITT eradication rates were 91.1% (95% CI: 87%-95%) and 90% (95% CI: 86%-94%) | 14-d bismuth- and levofloxacin-containing quadruple therapy is effective second-line therapy in patients whose sequential or concomitant therapies have failed |
| Amoxicillin 1 g b.d., esomeprazole 40 mg b.d., levofloxacin 500 mg o.d. and bismuth 240 mg b.d. for 14 d | PP rates of eradication were greater than 90% for all regimens: 93.1% for LBTF (95% CI: 92.4%-99.8%), 94.6% for LBAT (95% CI: 90.3%-99.2%), and 99.0% for LBAF (95% CI: 97.0%-100%). The ITT response rates were 87.9% for LBTM (95% CI: 81.7%-94%), 91.7% for LBTF (95% CI: 87.1%-96.3%), 83.8% for LBAT (95% CI: 76.8%-90.9%), and 95.2% for LBAF (95% CI: 91.1%-99.3%) | Four bismuth-containing quadruple therapies achieved greater than 90% eradication of *H. pylori* in patients who did not respond to previous treatment, including patients with metronidazole resistance |
| Lansoprazole (50 mg twice daily) and bismuth potassium citrate (220 mg twice daily), along with 500 mg tetracycline and 400 mg metronidazole 4 times daily (LBTM), 500 mg tetracycline and 100 mg furazolidone 3 times daily (LBTF), 1000 mg amoxicillin 3 times and 500 mg tetracycline 4 times daily (LBAT), or 1000 mg amoxicillin and 100 mg furazolidone 3 times daily (LBAF) | Eradication rates ranged from 93.2% to 93.8% in the ITT population, and PP rates of eradication were greater than 90% for all regimens: 93.1% for LBTF, 91.7% for LBAT, and 95.2% for LBAF | Quadruple therapy containing furazolidone, instead of metronidazole, results in a significantly higher *H. pylori* eradication rate in Iranian duodenal ulcer patients |
| Amoxicillin 1000 mg, ranitidine 300 mg and bismuth subcitrate 240 mg b.d., with either furazolidone 200 mg b.d. (RAFB), or metronidazole 500 mg b.d. (RABM) for 2 wk | ITT eradication rates were 75% and 55% (P = 0.03) and per protocol eradication rates were 82% and 56% (P = 0.006) in the RAFB and RABM groups, respectively | A quadruple regimen of bismuth, metronidazole and tetracycline plus omeprazole produces a high eradication rate in subjects previously failing *H. pylori* eradication regimens |
| Tetracycline hydrochloride 375 mg, metronidazole 375 mg and bismuth subcitrate potassium 430 mg q.d.s., and omeprazole 20 mg b.d. for 10 d | Eradication rates ranged from 93.2% to 93.8% in the ITT population, and from 94.7% to 95.0% in the PP population | The 10-d bismuth quadruple therapies with high-dose metronidazole or levofloxacin were effective even in areas with high resistance. These two therapies were equally safe and tolerated |
| Tetracycline 500 mg q.d.s., esomeprazole 40 mg b.d. and bismuth subcitrate 300 mg q.d.s. plus either levofloxacin 500 mg once daily or metronidazole 500 mg q.d.s. for 10 d | ITT analysis revealed that both groups showed similar eradication rates: levofloxacin group, 78.9% (95% CI: 69.7%-88.1%) and metronidazole group, 79.7% (95% CI: 70.5%-88.7%) | Sequential or concomitant therapy with a PPI, amoxicillin, clarithromycin, and an imidazole agent are equally effective and safe for eradication of *H. pylori* infection. Concomitant therapy may be more suitable for patients with dual resistance to antibiotics. |
| Amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg esomeprazole 40 mg given twice a day for 10 d | ITT analysis demonstrated similar eradication rates for sequential 92.3% (95% CI: 87.5%-97.1%) and concomitant therapy 93.0% (95% CI: 88.3%-97.7%). PP eradication results were similar for sequential 93.1% (95% CI: 90.7%-95.5%) and concomitant therapy 93.0% (95% CI: 88.3%-97.7%) | Optimized non bismuth quadruple hybrid and concomitant therapies cured more than 90% of patients with *H. pylori* infections in areas of high clarithromycin and metronidazole resistance |
| Amoxicillin 1 g and omeprazole 40 mg twice daily for 14 d, clarithromycin 500 mg and nitroimidazole 500 mg twice daily (for the final 7 d) | In PP analysis, rates of eradication for hybrid and concomitant therapies were 92% and 96.1%, respectively. In ITT analysis, rates were 90% and 91.7% respectively | The 5 plus 5 d therapy as sequential therapy achieved sufficient eradication rate |
| Sequential therapy: Same 4 drugs taken concurrently, twice daily for 14 d | The eradication rate was 98% (95% CI: 94.3%-100%) with ITT analysis | The 5 plus 5 d therapy as sequential therapy achieved sufficient eradication rate |
| Amoxicillin 1 g b.d. plus omeprazole 20 mg b.d. for the first 5 d, followed by clarithromycin 500 mg b.d. tinidazole 500 mg b.d. and omeprazole 20 mg b.d., for the remaining 5 d | | 10-d sequential treatment achieves a higher eradication rate than standard triple therapy |
Amoxicillin 1000 mg b.i.d. and pantoprazole 40 mg b.i.d. for the first 5 d, followed by pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d. and metronidazole 500 mg b.i.d. in the remaining 5 d. 175

Comparison of standard triple therapy with a sequential schema represented two treatment groups did not differ with regard to H. pylori eradication rate for both ITT population (65.9% vs 71.4% for standard and sequential therapy respectively, \( P = 0.278 \)) and per protocol population (85.9% vs 74.1% for standard and sequential therapy respectively, \( P = 0.248 \)). In the present study, the two treatments resulted in similar rates of eradication, and both treatments were relatively ineffective.

Amoxicillin 1 g and lansoprazole 30 mg for the first 7 d or 5 d, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg for another 7 d or 5 d.

The eradication rate was 90.7% (95%CI: 87.4%-94.0%) in the 14 d, 87.0% (95%CI: 83.2-90.8) in the 10 d group, and 82.3% (95%CI: 78.0-86.6) in the triple therapy 14-d group. This study support to the use of sequential treatment as the standard first-line treatment for H. pylori infection.

Amoxicillin 1 g plus omeprazole 20 mg for the first 5 d, followed by 20 mg of omeprazole, 500 mg of clarithromycin, 500 mg of metronidazole, for the remaining 5 d.

The 10-d sequential therapy regimen failed to achieve significantly higher eradication rates than PPI-based triple therapy. The 10-d sequential therapy achieved 77.9% (60/77) by ITT and 8.7% (60/70) by PP analysis, but eradication rates in PPI-based triple therapy were 71.6% (58/81) and 76.6% (58/76) by ITT and PP analysis, respectively. The 10-d sequential therapy regimen failed to achieve significantly higher eradication rates than PPI-based triple therapy.

Amoxicillin 1 g b.d. plus PPI b.d. for the first 5 d, followed by a PPI b.d. clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the next 5 d.

The eradication rate was 84.2% (95%CI: 77%-90%) and the PP cure rate 90.7% (95%CI: 84%-95%). Sequential treatment seems highly effective for eradicating H. pylori.

Amoxicillin 1 g plus omeprazole 20 mg followed by 5 d omeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg or followed by 5 d omeprazole 20 mg, levofloxacin 250 mg and tinidazole 500 mg or followed by 5 d omeprazole 20 mg, levofloxacin 500 mg and tinidazole 500 mg twice daily.

Eradication rates in the ITT analyses were 80.8% (95% CI: 72.8%-87.3%) with clarithromycin sequential therapy, 96.0% (95% CI: 90.9%-98.7%) with levofloxacin-250 sequential therapy, and 96.8% (95% CI: 92.0%-99.1%) with levofloxacin-500 sequential therapy. Levofloxacin-containing sequential therapy is more effective, equally safe and cost-saving compared to a clarithromycin-containing sequential therapy.

The first rescue therapy including high-dose PPI dual therapy with amoxicillin or rabeprazole for 2 wk was highly tolerable and the PP and ITT success rate was 75.4% and 71.8% which was less than the second rescue therapy with amoxicillin and rabeprazole and levofloxacin.

In the study of Ince et al, dual therapy containing high-dose PPI (omeprazole) and amoxicillin was more cost-effective, successful and safe compared to standard triple therapy in patients with dyspepsia.

A prospective, open-label pilot study of H. pylori eradication revealed that 2-wk dual regimen of twice a day high-dose long acting lansoprazole plus amoxicillin treatment success was not acceptable.

Based on a large-scale multihospital trial study, high-dose dual therapy containing rabeprazole and amoxicillin is superior to standard regimens as sequential therapy or triple therapy for H. pylori infection, with similar safety profiles and tolerability.

If the theory, that consistently high intra gastric pH is required to reliably achieve more than 90% H. pylori eradication, the some mentioned studies results do not confirmed this theory. It seems many regiments were not sufficient to eradicate H. pylori.

**Triple therapy**

Triple H. pylori therapy comprising a PPI, amoxicillin and clarithromycin is used as the firstline therapy. Clarithromycin or metronidazole resistance has been related to a reduction of success rates, making it a significant reason leading to treatment failure of H. pylori. The other factors such as rapid metabolism of PPIs by CYP2C19, poor patient compliance, high acidity of stomach and bacterial load seem to be the main causes of eradication failure. One hundred and thirty-six patients enrolled in the study of 10-d triple therapy comprising esomeprazole plus amoxicillin and metronidazole. Cure rates of patients were 82.4% by ITT analysis and 88.2% by PP analysis.
Based on several available clinical trials, it seems that a quinolone-based triple therapy will be operative as the first-line therapy in *H. pylori* infection[11]. The use of levofloxacin as an alternative of clarithromycin in triple and sequential therapies has been investigated by Qian et al.[48] 7-d levofloxacin based triple therapy (levofloxacin, amoxicillin, esomeprazole) generated unsatisfactorily therapeutic efficiency, only levofloxacin-containing sequential therapy reached adequate outcome.

The effectiveness of a triple bismuth-consisting regimen along with amoxicillin and nifuratel used for eradication of *H. pylori* in patients were evaluated. The results of this study revealed the therapy containing bismuth subcitrate, amoxicillin and nifuratel yielded a success rate of 86% in childhood[49]. Standard dose (amoxicillin 1 g, clarithromycin 500 mg and rifabutin 150 mg, all two times per day for 10 d) vs half dose regimen in therapy of *H. pylori* infected subjects was equally efficient and better tolerated[50]. The results of triple therapy containing clarithromycin, amoxicillin and esomeprazole 40 mg or omeprazole 20 mg in different genotypes of CYP2C19 showed that esomeprazole containing regimen increased eradication rate in comparison with the triple therapy based on omeprazole in extensive metabolizers of CYP2C19. Regardless to genotyping of CYP2C19 the *H. pylori*, eradication rates remained similarly comparable among the omeprazole and the esomeprazole group[51].

One thousand four hundred and sixty-three *H. pylori* infected participated in a study to compare 10-d sequential, 14-d triple and 5-d concomitant therapies. The best eradication efficacy has been reported by standard 14-d triple therapy followed by sequential 10-d therapy[52].

**Quadruple therapy**

Quadruple therapy comprising bismuth subcitrate, PPI, metronidazole and tetracycline has been accepted better than standard triple therapy in several studies[53-55]. Ten-days quadruple therapy containing bismuthate dicitrate, esomeprazole, levofloxacin and tetracycline showed success rate of 95.8% after the failure of sequential therapy. This regimen could be used as a good choice in high clarithromycin resistance areas[56]. In a similar study 14-d therapy with esomeprazole, amoxicillin, levofloxacin, and bismuth achieved more than 90% eradication rate after the failed sequential or concomitant therapies[57].

Four hundred and twenty-four patients (96.8% metronidazole resistance) did not respond to standard therapies treated by lansoprazole, bismuth potassium citrate plus (tetracycline and metronidazole or tetracycline and furazolidone or amoxicillin and tetracycline or amoxicillin and furazolidone) which all bismuth-containing quadruple therapies reached higher than 90% success rate[58].

The efficiency of quadruple *H. pylori* therapy has been confirmed as the first-line regimen in a randomized trial. During this study, 14-d quadruple therapy was compared with 7-d standard therapy. Fourteen-days quadruple therapy comprising bismuth, PPI, amoxicillin and clarithromycin exhibited acceptable success rate and could be prescribed as the first line therapy[59].

An open alabel, randomized, phase 3 trial compared 10-d quadruple therapy with 7-d standard therapy in 440 patients. The quadruple therapy produced higher success rates (80%) in comparison with standard triple therapy (55%). Quadruple therapy could be accepted as the first line of treatment because of increased incidence of clarithromycin-resistant. In addition, quadruple therapy showed higher eradication rate but comparable side effects with standard therapy[60].

One hundred and six Iranian duodenal ulcer patients participated in the study of furazolidone in comparison with metronidazole during a quadruple therapy for eradication of *H. pylori* infection. In furazolidone group eradication rate was 75% and 82% (in ITT and PP analysis) but in metronidazole group 55% and 56% respectively[61].

Sixty-four patients who failed previous clarithromycin, amoxicillin and omeprazole, (standard triple treatment) eradication treatment were treated for 10 d with tetracycline, bismuth subcitrate potassium and metronidazole four times per day and omeprazole two times per day. According to results, *H. pylori* eradication rates were between 93.2% to 95.0%[62].

One hundred and fifty patients in high resistance area were enrolled in a study to evaluate levofloxacin-containing quadruple therapy or high dose metronidazole plus bismuth subcitrate, esomeprazole, and tetracycline. Eradication rates were similar in both groups. Thus, metronidazole is a good choice because it is cheaper and more feasible[63].

Concomitant quadruple therapy is a non-bismuth quadruple based therapy comprising omeprazole, metronidazole, amoxicillin, and clarithromycin during 5 to 7 d[64,65]. The consequence of a meta-analysis of several randomized trials exhibited that concomitant quadruple therapy has been better than standard triple therapy[66] in addition, another meta-analysis of 2070 patients also confirmed this result[66].

Resistance to both metronidazole and clarithromycin considerably influence sequential therapy but did not affect the success rate of concomitant quadruple therapy. In addition, concomitant regimen has been confirmed to be safe and similarly active like sequential therapy in eradication of *H. pylori*[67]. In an area that 23.5% of subjects had clarithromycin resistant *H. pylori* strains, (33% resistant to metronidazole and 8.8% resistant to both drugs), the efficacy of 2 different optimized nonbismuth quadruple regimens was compared. According to the results, concomitant quadruple therapy with omeprazole, amoxicillin, clarithromycin and nitroimidazole two times a day for 14 d showed more than 90% cure rate of *H. pylori*[68].
**Sequential therapy**

An Italian innovation in the quadruple therapy leads to sequential therapy comprising dual therapy for 5 d with amoxicillin and PPI and 5 more days with tinidazole, clarithromycin and PPI\(^{[69]}\). This regimen was studied among 52 patients suffering from *H. pylori* infection and eradication rate around 98% was achieved with ITT analysis\(^{[70]}\). The other study which assessed the success rate of treatment by sequential therapy in compare with standard triple therapy showed that 10-d sequential therapy was better than standard triple therapy in children, that is confirmed by the researches done on adults\(^{[71]}\).

A retrospective study compared eradication treatment in subjects that underwent triple treatment consisting of clarithromycin, PPI and amoxicillin or sequential treatment involving a clarithromycin, PPI and amoxicillin, and metronidazole in a high anti-microbial resistance setting. Eradication rate of *H. pylori* was comparable between the two treatment groups\(^{[72]}\).

Two recently meta-analysis studies established above mentioned data, according to Jafri *et al*\(^{[73]}\), review *H. pylori* treatment in 2747 patients. Success rates were 93.4% in sequential regimen where as 76.9% in common triple therapy.

The influence of different factors on success rate of *H. pylori* eradication assessed using two therapy regimens (sequential and triple therapy) for equal 10-d period of study. The data suggested that traditional factors such as smoking and *CagA* gene change efficacy of triple therapies but did not affect sequential therapy\(^{[74]}\).

Ten-days sequential regime consisted of amoxicillin plus a PPI for 5 d, was continued by clarithromycin, metronidazole and a PPI for more 5 d demonstrated higher efficacy of triple therapy\(^{[75]}\). In another study 900 patients were examined for sequential therapy comprising amoxicillin and lansoprazole for 7 d continued by metronidazole, lansoprazole, and clarithromycin vs standard triple therapy. In the outcome, success rate was 90.7% in sequential therapy but 82.3% in triple therapy\(^{[76]}\).

Cure rate of the sequential therapy was altered based on the type of used nitro imidazole, on the other hand, a therapy program with metronidazole provided results which were not as good as tinidazole\(^{[69]}\). Certainly, the results of Choi *et al*\(^{[77]}\), study showed that *H. pylori* eradication rate was 77.9% of subjects treated by a metronidazole-based 10-d sequential regimen\(^{[78]}\) compared to the results of the other study which indicated 97.4% of treatment by a tinidazole-based regimen. Eradication rate was 84.2% in the other metronidazole-based sequential therapy which was less than tinidazole-based therapy\(^{[75]}\). Most likely, such occurrence is because of longer half-life of tinidazole vs metronidazole\(^{[79]}\).

In high clarithromycin resistance areas, clarithromycin substitution by levofloxacin has been investigated. Levofloxacin sequential therapy showed eradication rate more than 96% in comparison with 80.8% clarithromycin sequential therapy\(^{[79]}\). Levofloxacin-based sequential regimen is better than usual triple therapy as the first line in the sites with high incidence of resistance to clarithromycin\(^{[80]}\).

Recently a retrospective study has been done among subjects that underwent triple treatment consisting of clarithromycin, amoxicillin and a PPI or sequential treatment involving amoxicillin, a PPI, clarithromycin, and metronidazole eradication treatment in a high antimicrobial resistance setting. The *H. pylori* eradication rate was not statistically different between the 2 treatment groups\(^{[72]}\).

**FUTURE PERSPECTIVES**

Overuse of antibiotics and accumulation of point mutations in the *H. pylori* DNA is intended as the main cause of the increase in antibiotic resistance\(^{[81]}\).

In the present, the recommendation of antibiotics for two weeks or high-dose PPI are commonly associated with the development of undesirable side effects and complaints during anti-*H. pylori* therapy\(^{[82]}\). A large number of *H. pylori* eradication reports from different geographic areas are indicating conflicting results and a treatment regimen may be extremely efficient in one geographic area and deliver unsatisfactory results in another\(^{[83]}\). In 2010, An *H. pylori* strain was isolated from a 31-year-old woman with gastric cancer that was resistant to all seven antibiotics that were tested: Clarithromycin, metronidazole, amoxicillin, tetracycline, furazolidone, erythromycin and ciprofloxacin\(^{[84]}\). Finding new molecules for treatment of *H. pylori* infection is a part of ongoing research programs\(^{[85-86]}\).

Therefore, the development of a new and alternative treatment regimen for the eradication of *H. pylori* which also reduces the frequency of adverse effects would be an invaluable advancement.

**PROBIOTICS**

The probiotics, live microorganisms mostly within *Lactobacillus*, *Bifido bacterium* and *Saccharomyces* genus which, when administered in sufficient amounts, exert a health benefit on the host beyond inherent basic nutrition\(^{[93,94]}\).

Current interest in probiotic effectiveness against *H. pylori* and its activity in reducing bacterial colonization and decreasing gastric inflammation have been stimulated because it provides a large-scale and low-cost alternate solution to prevent or decrease *H. pylori* colonization\(^{[94-97]}\).

A number of mechanisms have been anticipated for probiotic efficacy against *H. pylori*. Probiotic bacteria can modulate *H. pylori* activity by either immunological (e.g., increment of serum IgA and reduction in cytokine profiles such as IL-6) or non-immunological mechanisms (antagonism and competition with potential pathogens\(^{[97-100]}\).

The studies those using probiotics alone, showed...
only partial improvement in probiotics efficacy against H. pylori, while administration of probiotics with eradication regimens lead to increase in efficacy and/or reduction of side effects\textsuperscript{[98,101,102]}. However, conflicting data have been obtained with probiotics treatment\textsuperscript{[103]}. Addition of yogurt to PPI-based triple therapy improved the eradication rate but side effects were the same to that in the control group with standard triple therapy\textsuperscript{[103]}

The effect of probiotic supplementation on H. pylori eradication and side effects which was conducted on May 2014 showed that specific strains of probiotics supplementation can improve rates of eradication specially when antibiotic therapies are relatively inefficient. This meta-analysis observed no significant decrease of side effects so that, noticeable heterogeneity was observed for the overall occurrence of adverse events\textsuperscript{[100]}

In another study addition of bovine lactoferrin leads to increase in the eradication rate of H. pylori, and probiotics reduced the side effects of antibiotic therapy in the standard triple treatment\textsuperscript{[105]}. Dajani et al\textsuperscript{[106]}, designed a study to evaluate the effect of adding the probiotic Bifidus infantis to triple therapy or pretreatment by probiotic before triple therapy. They showed pre-treatment with 2 wk of B. infantis before standard triple therapy increased the eradication rate to 90.5% in compare with triple therapy plus probiotic (83%) and triple therapy alone (68.9%)\textsuperscript{[106]}

The effectiveness of probiotics in a standard triple H. pylori therapy which analyzed in a systematic review and meta-analysis study suggests that supplementation of a standard triple therapy regimen with probiotics improved the H. pylori eradication rates specially in Asian patients and the prevalence of total side effects\textsuperscript{[105]}

The other meta-analysis, by Lv et al\textsuperscript{[107]}, in 2015 compared the probiotics as adjuvant agents of anti-H. pylori standard triple therapy regimens with placebo or no treatment. It was concluded that supplementing triple H. pylori therapy regimens with probiotic can enhance eradication rates and reduce the adverse events occurred during eradication treatment. Administration of probiotic before or subsequent to eradication treatment for a duration of > 2 wk probably improve the eradication efficacy\textsuperscript{[107]}. Probiotic pretreatment plus quadruple therapy can decrease H. pylori loads despite antimicrobial resistance, thus increasing the treatment efficacy of quadruple therapy in the H. pylori eradication\textsuperscript{[108]}

A randomized, prospective, double-blind, placebo controlled study corresponding to 100 H. pylori-positive naive patients demonstrated Lactobacillus reuteri combination alone is capable of exerting an inhibitory activity against H. pylori, and when administered with eradication therapy, it increases eradication rates by about 9% and cause a significant reduction in antibiotic related adverse events\textsuperscript{[109]}

The use of probiotics, as adjuvant therapy, appears promising for the current H. pylori eradication treatment, in order to reduce the frequency of antibiotic induced side-effects, though it still requires optimization\textsuperscript{[110,111]}

**HERBAL COMPOUNDS**

In recent years, a number of studies have suggested that phytomedicine has a complementary function in H. pylori treatment, and H. pylori infection can be prevented through the use of inexpensive, safe and non-toxic anti-H. pylori formulations from medicinal plants. Many plant extracts, partially purified reactions and natural compounds with the anti-H. pylori activity has been reported\textsuperscript{[3,112-114]}. Some bioactive compounds from medicinal plants with anti-H.pylori activity include carvacrol\textsuperscript{[115]}, polyphenolic catechins\textsuperscript{[116]}, tannins\textsuperscript{[111]}, cinnamaldehyde, eugenol\textsuperscript{[117]}, quercetin\textsuperscript{[118]}, licorice, licoisoflavone B\textsuperscript{[119]}, Berberine, sanguinarine, chelythrynine, protopine, β-hydrastine\textsuperscript{[120]}, mastic\textsuperscript{[121,122]}, plumbagin\textsuperscript{[123]}, protocatechuic acid\textsuperscript{[124]}

Concerning the reducing power of plant extracts on antibiotic resistance, the anti-mutagenic properties of some plant extracts on the incidence of mutations conferring resistance to clarithromycin in H. pylori was evaluated. The results of this study showed the considerable efficacy of Mirtus communis, Teucrium polium extracts in prohibiting antibiotic resistance. This may be more beneficial if the medicinal plants in combination with present antibiotic regimens are used to develop more effective eradication regimens\textsuperscript{[125]}

However, mode of action, potential cytotoxicity and benefits of herbal medicine are complex, incomplete and confusing\textsuperscript{[126]}. Further evaluation of pharmacokinetics for those products in animals and the design of precise clinical trials of promising herbal products should be addressed in future investigations.

**PHOTODYNAMIC THERAPY**

Photodynamic inactivation of microorganisms is on the basis of the combination of a dye known as a sensitizer or photo sensitizer and harmless visible light of an appropriate wavelength to generate the triplet excited state (2O2) of the dye molecules which, in turn, may react with molecular oxygen which lead to production of different cytotoxic reactive oxygen species such as superoxide radical-anion (O2•-) and singlet molecular oxygen (O2)\textsuperscript{[127,128]}

Recently, some in vitro\textsuperscript{[129-131]} and in vivo\textsuperscript{[132,133]} studies to develop anti-H. pylori photodynamic therapy for the eradication of H. pylori were successful\textsuperscript{[134]}

In an in vitro study, a photosensitizer such as Chlorin e6 (Ce6) as a natural product reduced from chlorophyll, was used to achieve an optimal irradiation conditions like initial Ce6-concentration, incubation time, light intensity and exposure time for an effective inactivation of H. pylori. Photodynamic inactivation of H. pylori using Ce6 shows that the exposure time of irradiation, followed by the light intensity and the concentration of Ce6 were the major cause of strains inactivation\textsuperscript{[130]}
Hamblin et al.\textsuperscript{[131]} demonstrated multiple strains of \textit{H. pylori} are killed \textit{in vitro} by photodynamic action upon illumination.

\textit{H. pylori} is sensitive to inactivation by blue light which may represent a novel therapy approach especially in patients with failed standard antibiotic therapy. Blue light phototherapy produces a rapid decline of bacterial numbers in endoscopically delivered blue light in the gastric antrum of the 10 patients who were positive for the \textit{H. pylori}\textsuperscript{[133]}

Based on a controlled, prospective pilot study, intra-gastric violet light phototherapy is safe and feasible and may demonstrate a new approach for \textit{H. pylori} eradication, particularly in patients who have failed therapy with standard antibiotic regimens\textsuperscript{[132]}

Choi et al.\textsuperscript{[129]} applied endoscopic white light and methylene blue dye to show impressive antibacterial effect against \textit{H. pylori}. The primary mechanism of the bactericidal effect has been shown to be oxidative DNA damage of \textit{H. pylori}\textsuperscript{[129]}

\textit{In vitro} photodynamic therapy against \textit{H. pylori} using endoscopic light (NBI and conventional white light), with low or high concentration of protoporphyrin IX as a photosensitizer revealed the bactericidal activities are very efficient and the main mechanism of this photodynamic therapy involves damage to the cell membrane\textsuperscript{[134]}

According to the results, it is necessary to perform \textit{in vivo} photodynamic therapy using animal model of disease and indicate the limitations and effectiveness of this novel technique. Also the cost, side effects and ease of administration should be also taken into account and develop new photosensitizer materials to improve the antibacterial activity or using light of a wavelength specific to the photosensitizer instead of light of a broad wavelength spectrum\textsuperscript{[127,129]}

\section*{VACCINE}

All known gastric \textit{H. pylori} species are urease positive that catalyze the hydrolysis of urea. UreB is the relatively conserve urease activity unit and It has very strong antigenicity and is the critical for the bacterial survival and colonization under acidic condition of the stomach. UreI, a \textit{H. pylori} urea channel protein, is a key factor for bacterial colonization in acidic mammalian stomach\textsuperscript{[135]}

In a research, a multi-epitope vaccine was designed by coupling two antigenic fragments (UreB and UreI ) of \textit{H. pylori} and cholera toxin B subunit (CTB), resulting considerable protection effects against \textit{H. pylori} challenge in BALB/c mice\textsuperscript{[136]}

Both intramuscular injection and oral administration of multi-epitope antigen, UreI and UreB, with CTB had immune protective effect against \textit{H. pylori} challenge, and oral administration had the higher infection protection rate against \textit{H. pylori}\textsuperscript{[135]}

Several other \textit{H. pylori} proteins have already been reported as effective vaccine antigens such as cytotoxin-associated gene A, vacuolating cytotoxin A (Vac A)\textsuperscript{[137]} heat-shock proteins\textsuperscript{[138]}, neutrophil-activating protein\textsuperscript{[139]}, surface-localized protein HpaA\textsuperscript{[140]} and so on. It is probable a combination of some mentioned antigens with each other or with a suitable adjuvant may induce a protective effect through vaccination\textsuperscript{[140,141]}

Recently, a reverse vaccinology approach was employed to predict the potential vaccine candidates against \textit{H. pylori} and search novel antigens using computational methods or bioinformatics. In this study, 5 antigenic epitopes including adhesion protein babA, sabA, omp16, iron (III) dicitrate transport protein fecA and vacuolating cytotoxin vacA have been prioritized as potential vaccine candidates against \textit{H. pylori} infections\textsuperscript{[140]}

Therapeutic antibodies present valuable tools in targeting a wide range of enteric diseases and pathogens during the years\textsuperscript{[143]} A recent study by den Hoed et al\textsuperscript{[144]} has shown monotherapy with bovine antibody-based oral immunotherapy is well tolerated, but does not significantly reduce intragastric \textit{H. pylori} density in humans\textsuperscript{[144]}

The generation and application of virus-like particles and nanobeads with a surface adsorbed antigen that can elicit strong T and B cell immune responses would be as a useful tool for the development of vaccines\textsuperscript{[145]} The development of safe and effective vaccine against \textit{H. pylori} infection becomes particularly important.

\section*{CONCLUSION}

The use of antibiotics as first-line therapies may be appropriate if they are selected based on country-wide studies of the local and regional antimicrobial resistance patterns. Development of alternative antibiotics for the eradication of \textit{H. pylori} would be an invaluable advancement, although it takes number of years before to evaluate these potentially interesting molecules in humans.

Adjuvant therapy with probiotics is recommended due to immunomodulation, stimulation of mucin production and inhibition of colonization and survival of \textit{H. pylori}. On the other hand, potential options such as medicinal plants, Photodynamic therapy and vaccine are still in the experimental phase.

\section*{REFERENCES}

1. Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol 2015; 21: 2522-2533 [PMID: 25741163 DOI: 10.3748/wjg.v21.i8.2522]

2. Hajimahmoodi M, Shams-Ardakani M, Sanjee P, Siavoshi F, Mehrabani M, Hosseinзадeh H, Foroumadi P, Safavi M, Khamavi M, Akbarzadeh T, Shafee A, Foroumadi A. In vitro antibacterial activity of some Iranian medicinal plant extracts against Helicobacter pylori. Nat Prod Res 2011; 25: 1059-1066 [PMID: 21726128 DOI: 10.1080/14786419.2010.501763]

3. Buzás GM. Metabolic consequences of Helicobacter pylori infection and eradication. World J Gastroenterol 2014; 20: 5226-5234 [PMID: 24833852 DOI: 10.3748/wjg.v20.i18.5226]
Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol 2015; 13: 1616-1626 [PMID: 25681693 DOI: 10.1016/j.cgh.2015.02.005]

Karakonstantis GP, Diakos OL, Xouris D, Goukos D, Delladetsima I, Ladas SD. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. Digestion 2014; 90: 229-231 [PMID: 25351953 DOI: 10.1159/000369898]

Khademi F, Poursina F, Hosseini E, Akbari M, Safaei HG. Helicobacter pylori in Iran: A systematic review on the antibiotic resistance. Iran J Basic Med Sci 2015; 18: 2-7 [PMID: 25810869]

Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10: 528-534 [PMID: 19066606]

Sachs G, Shin JM, Driving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+K+-ATPase. Annu Rev Pharmacol Toxicol 1995; 35: 277-305 [PMID: 7598495 DOI: 10.1146/annurev.pa.35.040195.001425]

Fellenius E, Berglindth L, Sachs G, Olsbe L, Elander B, Sjöstrand SE, Wallmark B. Substituted benzimidazoles inhibit gastric catalytic secretion by blocking (H+ + K+)ATPase. Nature 1981; 290: 159-161 [PMID: 6295357]

Shin JM, Besancon M, Simon A, Sachs G. The site of action of pantoprazole in the gastric H+/K+-ATPase. Biochim Biophys Acta 1993; 1148: 223-233 [PMID: 8389196]

Shin JM, Sachs G. Differences in binding properties of two proton pump inhibitors on the gastric H+ + K+ATPase in vivo. Biochem Pharmacol 2004; 68: 2117-2127 [PMID: 15498502]

Spengler G, Molnar A, Klauss G, Mandi Y, Kawase M, Motoshashi N, Molnar J. Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and -resistant Helicobacter pylori. Int J Antimicrob Agents 2004; 23: 631-633 [PMID: 15194136 DOI: 10.1016/j.ijantimicag.2003.11.010]

Kita T, Tanigawara Y, Aoyama N, Hohda T, Saijoh Y, Komada F, Sakaeda T, Okumura K, Sakai T, Kasuga M. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res 2001; 18: 615-621 [PMID: 11465146]

Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008; 47: 1-6 [PMID: 18076214]

Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44: 297-302 [PMID: 16961157]

Lim PW, Goh KL, Wang BC. CYP2C19 genotype and the PPIs-focus on rabeprazole. J Gastroenterol Hepatol 2005; 20 Suppl: S22-S28 [PMID: 15639346]

Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu JF, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20: 1609-1603 [PMID: 25473155 DOI: 10.3748/wjg.v20.i43.16029]

Kuo CH, Wang SS, Hsu WH, Kuo FC, Weng BC, Li CJ, Hsu PI, Chen A, Hung WC, Yang YC, Wang WM, Wu DC. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter 2010; 15: 265-272 [PMID: 20633187 DOI: 10.1111/j.1572-3579.2010.00761.x]

Lundell L, Havu N, Miettinnen P, Myrvold HE, Wallin L, Julkunen R, Levander K, Hatlebakk JG, Liedman B, Lamm M, Malm A, Walan A. Changes of gastric mucosalarchitecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23: 539-647 [PMID: 16486903]

Hagihara T, Mukaiishi K, Nakayama T, Hattori T, Sugihara H. Proton pump inhibitors and helicobacter pylori-associated pathogenesis. Asian Pac J Cancer Prev 2015; 16: 1315-1319 [PMID: 25743791]

de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMD 2000; 320: 31-34 [PMID: 10617524]

Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose
proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. *Helicobacter* 2016; 19: 90-97 [PMID: 24506175 DOI: 10.1111/hel.12106]

De Franceso V, Jerardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. *World J Gastroenterol* Ther 2012; 3: 68-73 [PMID: 22966485 DOI: 10.4202/wjgpt.v3.i48.68]

Attum TA, Graham DY. Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. *J Gastroenterol Hepatol* 2012; 27: 59-61 [PMID: 21793914 DOI: 10.1111/j.1440-1746.2011.06876.x]

Attum TA, Graham DY. High-dose extended-release lansoprazole (delxansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. *Helicobacter* 2014; 19: 319-322 [PMID: 24698653 DOI: 10.1111/hel.12126]

Graham DY. Javed SU, Keihanian S, Abudayyeh S, Opeken AR. Dual proton pump inhibitor plus amoxicillin as an empiric H. pylori therapy: studies from the United States. *J Gastroenterol* 2010; 45: 816-820 [PMID: 20195646 DOI: 10.1007/s00535-010-0220-x]

Goh KL, Manikam J, Qua CS. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. *Aliment Pharmacol Ther* 2012; 35: 1097-1102 [PMID: 22404486 DOI: 10.1111/j.1365-2036.2010.05054.x]

Ince AT, Touzlu M, Baysal B, Şentürk H, Arıcı S, Özden A. Yields of dual therapy containing high-dose proton pump inhibit tor in eradication of H. pylori positive dyspeptic patients. *Hepatogastroenterology* 2014; 61: 1454-1458 [PMID: 25513109]

Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Sheih MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. *Clin Gastroenterol Hepatol* 2015; 13: 895-905.e5 [PMID: 25460556 DOI: 10.1016/j.cggh.2014.10.036]

Yoon K, Kim N, Nam RH, Suh JH, Lee S, Kim JM, Lee JY, Kwon HY, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea. *J Gastroenterol Hepatol* 2015; 30: 490-495 [PMID: 25363555 DOI: 10.1111/j.1440-1746.2014.05930.x]

Sánchez-Delgado J, García-Iglesias P, Castro-Fernández M, Bory B, Barenys M, Bujanda L, Lisozain J, Calvo MM, Torra S, Gisbert J, Sánchez-Delgado J. Efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for eradication of Helicobacter pylori infection after failure of sequential therapy. *Helicobacter* 2014; 19: 74-79 [PMID: 24033865 DOI: 10.1111/hel.12085]

Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. *Clin Gastroenterol Hepatol* 2013; 11: 802-807.e1 [PMID: 23376004 DOI: 10.1016/j.cgh.2013.01.008]

Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. *Helicobacter* 2010; 15: 233-238 [PMID: 20557366 DOI: 10.1111/j.1535-3737.2010.00758.x]

Malfertheiner P, Bazzoli F, Delchier JC, Celis K, Giguère M, Rivièrè M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011; 377: 905-913 [PMID: 21345487 DOI: 10.1016/S0140-6736(11)60026-0]

Malezkadeh R, Ansari R, Vahed H, Siavoshi F, Alizadeh BZ, Eshraghian MR, Vakili A, Saghari M, Massarvat S, Faruzolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. *Aliment Pharmacol Ther* 2000; 14: 299-303 [PMID: 10735922 DOI: 10.1046/j.1365-2036.2000.00709.x]

Delchier JC, Malfertheiner P, Thieffod-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. *Aliment Pharmacol Ther* 2014; 40: 171-177 [PMID: 24886385 DOI: 10.1111/apt.12808]

Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. *J Antimicrob Chemother* 2013; 68: 222-228 [PMID: 22984204 DOI: 10.1093/jac/dks361]

Okada M, Oki K, Shirotani T, Seo M, Okabe N, Maeda K, Nishimura H, Okuma K, Oda K. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. *J Gastroenterol* 1998; 33: 640-645 [PMID: 9773927 DOI: 10.1007/s005350050150]

Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/
metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3: 54-58 [PMID: 9546119]

65 Essa AS, Kramer JR, Graham DY, Treibher G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 109-118 [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671.x]

66 Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34 [PMID: 22457599 DOI: 10.1158/1535-8982.CEG-12-0149]

67 Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41.e1 [PMID: 19804842 DOI: 10.1016/j.cgh.2009.09.030]

68 Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez M, Martinez-Alcalá C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazo-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-128.e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]

69 Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential Therapy for Helicobacter pylori Eradication: The Time is Now? Therap Adv Gastroenterol 2009; 2: 317-322 [PMID: 21185079 DOI: 10.1177/1756283X09343326]

70 Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomaselli G, Attili AF. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-718 [PMID: 10848654 DOI: 10.1046/j.1365-2036.2000.00766.x]

71 Francavilla R, Lionetti E, Castellana SP, Magistà AM, Boscarelli G, Piccietti D, Amoruso A, Di Leo A, Minnoli VL, Francavilla A, Cavalllo L, Ierardi E. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005; 129: 1414-1419 [PMID: 16285942 DOI: 10.1053/j.gastro.2005.09.007]

72 Dolapiçoglu C, Koc-Yesiltoprak A, Ahishali E, Kural A, Zullo A, Hassan C, Fiorini G, Vakil N. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-1470 [PMID: 20497881 DOI: 10.1136/gut.2010.215359]

73 Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C, Mateos-Rodriguez JM, Gonzalez-Garcia G, Abadía EG, Gisbert JP. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-1084 [PMID: 20180787 DOI: 10.1111/j.1365-2036.2010.04274.x]

74 Boyanova I. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol 2009; 58: 930-935 [PMID: 19502370 DOI: 10.1099/jmm.0.009993-0]

75 Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW, Harrison G, Trowell JE. Experience with ‘triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-435 [PMID: 1420735]

76 Ierardi E, Giangaspero A, Lounard G, Giorgio F, Amoruso A, De Francesco V, Di Leo A, Principi M. Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens. J Gastroenterostin Liver Dis 2014; 23: 367-370 [PMID: 25531993 DOI: 10.15403/jgld.2014.1121.234.qyth]

77 Abadi AT, Mobarez AM. First case of Helicobacter pylori infection resistant to seven antibiotics in Iran. Rev Soc Bras Med Trop 2014; 47: 666-667 [PMID: 25467273]

78 Asadipour A, Edraki N, Nakhjiri M, Yahya-Meymandi A, Alipour E, Saniee P, Siavoshi F, Shafeie A, Foroumadi A. Helicobacter pylori infection and Structure-Activity Relationship study of 2-Alkylthio-5-(nitroaryl)-1,3,4-thiadiazole Derivatives. Iranian J Pharm Res 2013; 12: 281-287 [PMID: 24250634]

79 Mohammadhosseini N, Saniee P, Ghamaripour A, Aryapour H, Afshar F, Edraki N, Siavoshi F, Foroumadi A, Shafeie A. Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitro)1,3,4-thiadiazole Derivatives. Iran J Pharm Res 2013; 12: 66 [PMID: 23924894 DOI: 10.1186/2008-2231-21-66]

80 Moshafi MH, Sorokhi M, Emami S, Nakhjiri M, Yahya-Meymandi A, Negahbani AS, Siavoshi F, Omrani M, Alipour E, Vosooghi M, Shafeie A, Foroumadi A. 5-Nitroimidazole-based 1,3,4-thiadiazoles: heterocyclic analogs of metronidazole as anti-Helicobacter pylori agents. Arch Pharm Res 2010; 33: 166 [PMID: 20983271 DOI: 10.1186/2008-2231-21-66]

81 Foroumadi A, Sorkhi M, Moshafi MH, Safavi M, Rineh A, Shafeie F, Alipour E, Emami S. 2-Substituted-5-nitroheterocycles: in vitro anti-Helicobacter pylori activity and structure-activity relationship study. Med Chem 2009; 5: 529-534 [PMID: 19673692]

82 Foroumadi A, Safavi M, Emami S, Siavoshi F, Najjari S, Safari F, Shafeie A. Structure-activity relationship study of a series of N-substituted piperazinyl-fluoroquinolones as anti-Helicobacter pylori agents. Med Chem 2008; 4: 498-502 [PMID: 18782047]

83 Ierardi E, Foroumadi A. Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-213 [PMID: 23158866 DOI: 10.1016/S0140-6736(12)61579-7]

84 Choi WH, Park DI, Oh SJ, Baek YH, Hong CH, Hong EJ, Song MJ, Park SK, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. [Effectiveness of 10-day sequential therapy for Helicobacter pylori eradication in Korea]. Korean J Gastroenterol 2008; 51: 280-284 [PMID: 18516011 DOI: 10.1097/MCG.0b013e3181a3a1a3]

85 Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36: 353-373 [PMID: 10384859 DOI: 10.2165/00003088-19993605-00004]

86 Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010; 59: 1465-1470 [PMID: 20497881 DOI: 10.1136/gut.2010.215359]
Safavi M et al. Helicobacter pylori infection treatment

Lett 2008; 18: 3315-3320 [PMID: 18442909 DOI: 10.1016/ j.bmcl.2008.04.033]

Mirzaei J, Siavoshi F, Emami S, Safari F, Khoshayand MR, Shafiei A, Foroumandi A. Synthesis and in vitro anti-Helicobacter pylori activity of N-[5-(5-nitro-2-hydroxyaryl)-1,3,4-thiadiazol-2-yl]thiomorpholines and related compounds. Eur J Med Chem 2008; 43: 1575-1580 [PMID: 18192086 DOI: 10.1016/j.ejmech.2007.11.019]

Prairiano MM, Iacono S, Francavilla R. Probiotics and Helicobacter pylori infection. Medicina Universitaria 2012; 14: 217-223

Linsalata M, Russo F, Berloco P, Caruso ML, Matteo GD, Cifone MG, Simone CD, Ierardi E, Di Leo A. The influence of Lactobacillus brevis on ornithine decarboxylase activity and polynucleotides in Helicobacter pylori-infected gastric mucosa. Helicobacter 2004; 9: 165-172 [PMID: 15068149]

Dore MP, Cuccu M, Pes GM, Manca A, Grahm DY. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med 2014; 9: 649-654 [PMID: 24178436 DOI: 10.1007/s11739-013-1013-z]

Pacilio L, Osborn JF, Bonec E, Romagazzi S, Baldini R, Chioca C. Probiotics for the treatment of Helicobacter pylori infection in children. World J Gastroenterol 2014; 20: 673-683 [PMID: 24574741 DOI: 10.3748/wjg.v20.i6.673]

Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20: 1450-1469 [PMID: 24587621 DOI: 10.3748/wjg.v20.i6.1450]

Patel A, Shah N, Prapajati JB. Clinical application of probiotics in the treatment of Helicobacter pylori infection—a brief review. J Microbiol Immunol Infect 2014; 47: 429-437 [PMID: 23757373 DOI: 10.1016/j.jmii.2013.03.010]

Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter 2012; 17: 297-304 [PMID: 22759330 DOI: 10.1111/j.1523-5378.2012.00941.x]

Ljung A, Wadström T. Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol 2006; 7: 73-89 [PMID: 16875422]

Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World Journal Gastroenterol 2013; 19: 8168-8180 [PMID: 24365066 DOI: 10.3748/wjg.v19.i45.8168]

Francavilla R, Lionetti E, Castellaneta S, Magistà AM, Lionetti E, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Helicobacter pylori activity of N-[5-(5-nitro-2-hydroxyaryl)-1,3,4-thiadiazol-2-yl]thiomorpholines and related compounds. Eur J Med Chem 2008; 43: 1575-1580 [PMID: 18192086 DOI: 10.1016/j.ejmech.2007.11.019]

Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008; 13: 261-268 [PMID: 18665934 DOI: 10.1111/j.1523-5378.2008.00601.x]

Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One 2014; 9: e111030 [PMID: 25365320 DOI: 10.1371/journal.pone.0111030]

de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F. Medicinal plant activity on Helicobacter pylori related diseases. World J Gastroenterol 2004; 10: 165-172 [PMID: 15068419]

Ramadan MA, Safwat NA. Antihelicobacter activity of aflatovoid compound isolated from Desmostachyabipinnata. J Aust Basic Appl Sci 2009; 3: 2270-2277

Fukai T, Muraki T, Akitani K, Kutsuna Y, Ishizawa K, Nakai Y. Antihelicobacter activity of aflavonoid compounds from licorice extract. Life Sci 2002; 71: 1449-1463 [PMID: 12172165]

Mahady GB, Pendland SL, Stoia A, Chadwick LR. In vitro susceptibility of Helicobacter pylori to isoxazoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis. Phytother Res 2003; 17: 217-221 [PMID: 12672149]

Ali SM, Khan AA, Ahmed I, Musaddiq M, Ahmed KS, Polasa H, Rao LV, Habibullah CM, Sechi LA, Ahmed N. Antimicrobial activities of Eugenol and Cinnamaldehyde against the human gastric pathogen Helicobacter pylori. Ann Clin Microbiol Antimicrob 2005; 4: 20 [PMID: 16371157]

Wang YC, Huang TL. High-performance liquid chromatography for quantification of plumbagin, an anti-Helicobacter pylori
A Novel Reduction Strategy of Clarithromycin Resistance in Helicobacter pylori. Jundishapur J Microbiol 2014; 7: e13081 [PMID: 25741431 DOI: 10.5812/jjm.13081]

Vale FF, Oleastro M. Overview of the phytomedicine approaches against Helicobacter pylori. World J Gastroenterol 2014; 20: 117-26 [PMID: 24914319 DOI: 10.3748/wjg.v20.i19.5594]

Calvino-Fernández M, Garcia-Fresnadillo D, Benito-Martínez S, McNicholl AG, Calvet X, Gishert JP, Parra-Cid T. Helicobacter pylori inactivation and virulence gene damage using a supported sensitizer for photodynamic therapy. Eur J Med Chem 2013; 68: 284-290 [PMID: 23988411 DOI: 10.1016/j.ejmech.2013.07.023]

Maiisch T. Anti-microbial photodynamic therapy: useful in the future? Lasers Med Sci 2007; 22: 83-91 [PMID: 17120167]

Choi SS, Lee HK, Chae HS. In vitro photodynamic antimicrobial activity of methylene blue and endoscopic white light against Helicobacter pylori 26695. J Photochem Photobiol B 2010; 101: 206-209 [PMID: 20692848 DOI: 10.1016/j.jphotobiol.2010.07.004]

Simón C, Mohracher C, Hüttenberger D, Bauer-Marschall I, Krickhahn C, Stachon A, Foth HJ. In vitro studies of different irradiation conditions for Photodynamic inactivation of Helicobacter pylori. J Photochem Photobiol B 2014; 141: 113-118 [PMID: 25463658 DOI: 10.1016/j.jphotobiol.2014.09.015]

Hamblin MR. Viveiros J, Yang C, Ahmadi A, Ganz RA, Tolkoff MJ. Helicobacter pylori accumulates photosensitizing porphyrins and is killed by visible light. Antimicrob Agents Chemother 2005; 49: 2822-2827 [PMID: 15980355]

Lembo AJ, Ganz RA, Shef S, Cave D, Kelly C, Levin P, Kazlas PT, Baldwin PC, Lindmark WR, McGrath JR, Hamblin MR. Treatment of Helicobacter pylori infection with intra-gastric violet light phototherapy: a pilot clinical trial. Lasers Surg Med 2009; 41: 337-344 [PMID: 19553762 DOI: 10.1002/lsm.20770]

Ganz RA, Viveiros J, Ahmad A, Ahmadi A, Khalil A, Tolkoff MJ, Nishiyak N, Hamblin MR. Helicobacter pylori in patients can be killed by visible light. Lasers Surg Med 2005; 36: 260-265 [PMID: 15791671]

Choi S, Lee H, Chae H. Comparison of in vitro photodynamic antimicrobial activity of protoporphyrin IX between endoscopic white light and newly developed narrow band endoscopic light against Helicobacter pylori 26695. J Photochem Photobiol B 2012; 117: 55-61 [PMID: 23076358 DOI: 10.1016/j.jphotobiol.2012.08.015]

Wang B, Pan X, Wang H, Zhou Y, Zhu J, Yang J, Li W. Immunological response of recombinant H pylori multi-epitope vaccine with different vaccination strategies. Int J Clin Exp Pathol 2014; 7: 6559-6566 [PMID: 25400734]

Yang J, Dai LX, Pan X, Wang H, Li B, Zhu J, Li MY, Shi XL, Wang BN. Protection against Helicobacter pylori infection in BALB/c mice by oral administration of multi-epitope vaccine of CTB-UreB-UreC. Pathog Dis 2015; 73: pii: fiv026 [PMID: 25846576]

Liu K, Shi Y, Luo P, Yu S, Chen L, Zhao Z, Mao XH, Guo G, Wu C, Zou QM. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model. Vaccine 2011; 29: 6679-6685 [PMID: 21745524]

Zhang H, Zhang X, Liu M, Zhang J, Li Y, Zheng CC. Expression and characterization of Helicobacter pylori heat-shock protein A (HpA) protein in transgenic tobacco (Nicotiana tabacum) plants. Biotechnol Appl Biochem 2006; 43: 33-38 [PMID: 16134969]

Tang RX, Luo DJ, Sun AH, Yan J. Diversity of Helicobacter pylori isolates in expression of antigens and induction of antibodies. World J Gastroenterol 2008; 14: 4816-4822 [PMID: 18720546]

Sutton P, Doidge C, Pinczower G, Wilson J, Harbour S, Swierczek A, Lee A. Effectiveness of vaccination with recombinant HpA from Helicobacter pylori is influenced by host genetic background. FEMS Immunol Med Microbiol 2007; 50: 213-219 [PMID: 17567282]

Flach CF, Svensson N, Blomquist M, Ekman A, Raghavan S, Holmgren J. A truncated form of HpA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 2011; 29: 1235-1241 [PMID: 21147129 DOI: 10.1016/j.vaccine.2011.11.088]

Naz A, Awan FM, Obaid A, Muhammad SA, Paracha RZ, Ahmad J, Ali A. Identification of putative vaccine candidates against Helicobacter pylori exploiting exoproteome and secretome: a reverse vaccinology based approach. Infect Genet Evol 2015; 32: 280-291 [PMID: 25818402 DOI: 10.1016/j.meegid.2015.03.027]

Jones RG, Martino A. Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. Crit Rev Biotechnol 2015; 15: 1-15 [PMID: 25600465]

den Hoed CM, de Vries AC, Mensink PB, Dierickx CM, Suzuki H, Capelle L, van Dekken H, Ouwendijk R, Kuipers EJ. Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: a randomized clinical trial. Can J Gastroenterol 2011; 25: 207-213 [PMID: 21523262]

Milani M, Sharifi Y, Rahmati-Yamchi M, Somi MH, Akbarzadeh A. Immunology and vaccines and nanovaccines for Helicobacter pylori infection. Expert Rev Vaccines 2015; 14: 833-840 [PMID: 25645086]
